Search Results
10
Everything
Search Filters
Organization
Purple Biotech Ltd.
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
March 05, 2025 07:00 ET
|
Purple Biotech Ltd.
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
February 18, 2025 07:00 ET
|
Purple Biotech Ltd.
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab...
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
February 03, 2025 07:00 ET
|
Purple Biotech Ltd.
Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer...
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
December 05, 2024 07:13 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
December 03, 2024 08:23 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
December 02, 2024 07:00 ET
|
Purple Biotech Ltd.
Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints A biomarker enriched patient population...
Purple Biotech Reports Third Quarter 2024 Financial Results
November 15, 2024 07:00 ET
|
Purple Biotech Ltd.
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers...
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
November 04, 2024 07:50 ET
|
Purple Biotech Ltd.
Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum...
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 25, 2024 07:20 ET
|
Purple Biotech Ltd.
CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell...
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 10, 2024 07:30 ET
|
Purple Biotech Ltd.
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer ...